dr. fauchi is a translator as much as as of us, when when they come together, it is try for hip, and i was thinking bl what to say after dr. voucher, i went back seven years ago, we did a bit of a sound track. three different. my favorite is that is "we are on a road to no where" by the talking heads. i don't think we are. if you go back, there it was a sense that we were investing and working hard not making progress're gress. somewhat on a road to no where. as we had it seemed that if they didn't know where you were going, they any can we weren't clear where we would take it all. what i am struck on, what an remarkably exciting time we are in now. i don't know when we will have a decade, i would urge you not to start counting too soon. one of the most exciting moments, in terms of where we are in a -- cape town, for research for pro -- google does a how important they are, how transformative. his no disease will be fully eliminated without one. all of the presentations that give you the latest on aids vaccine, research and development, as well as conversations about prefoalation, the the

dr. fauchi, over to you. thank you for coming. it is a pleasure to be here with you today. i am going to talk a bit about the issue of the role of an hiv vaccine. i want to start off by putting into perspective the concept of why we really do need an hiv hax vine, despite the spectacular successes, that we have had over the last several years, in the arenas of both treatment and prevention. take a look thea the background, then i will get into the nitty-gritty about where we are with the vaccine. we are all aware of the most recent numbers from un aids, that again, keep hiv aids, historically, among the short list, less than a handful of devastating pandemics that our civilization has to face, with stunning numberers, 75 million total tass, 39 million deaths, 35 million still living with hiv, as of the last count, 1.5 million deaths last year, 2.one million new infections, in the united states, we are a developed nation. we have drugs, health care, that is getting better. and it is really very difficult to accept one million living with hiv, 16 to 18 percent of them don't k

dr. fauchy has been working on this well over 30 years, in terms of the experience that we see. that's how we determine what's done with each and every group of people and different groups of people. that's how we base the decision. that's an individual basis often which is why we monitor directly and actively every day those health care workers that return. >> is the assessment -- i'll direct this to you, too, doctor, since you'll be in on this. in the assessment of risk difficult when people are coming from various countries and perhaps don't divulge where they've been? i know you can keep up with it to some extent. is the assessment tough to come by? >> several levels of assessment, first to assess the fever to see if someone is ill and then to determine the cause. second to see what exposures they may have had working in an ebola unit or are being a health care worker otherwise or having potential exposure to someone who may have had ebola. but for every one of the individuals who returns, we ask the states to undertake an active monitoring process and we facilitate that pro

dr. fauchy has been working on this well over 30 years, in terms of the experience that we see. that's how we determine what's done with each and every group of people and different groups of people. that's how we base the decision. that's an individual basis often which is why we monitor directly and actively every day those health care workers that return. >> is the assessment -- i'll direct this to you, too, doctor, since you'll be in on this. in the assessment of risk difficult when people are coming from various countries and perhaps don't divulge where they've been? i know you can keep up with it to some extent. is the assessment tough to come by? >> several levels of assessment, first to assess the fever to see if someone is ill and then to determine the cause. second to see what exposures they may have had working in an ebola unit or are being a health care worker otherwise or having potential exposure to someone who may have had ebola. but for every one of the individuals who returns, we ask the states to undertake an active monitoring process and we facilitate that pro

dr. fauchy has been working on this well over 30 years, in terms of the experience that we see. that's how we determine what's done with each and every group of people and different groups of people. that's how we base the decision. that's an individual basis often which is why we monitor directly and actively every day those health care workers that return. >> is the assessment -- i'll direct this to you, too, doctor, since you'll be in on this. in the assessment of risk difficult when people are coming from various countries and perhaps don't divulge where they've been? i know you can keep up with it to some extent. is the assessment tough to come by? >> several levels of assessment, first to assess the fever to see if someone is ill and then to determine the cause. second to see what exposures they may have had working in an ebola unit or are being a health care worker otherwise or having potential exposure to someone who may have had ebola. but for every one of the individuals who returns, we ask the states to undertake an active monitoring process and we facilitate that pro